Evaluation of cytochrome p450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions

Drug Metabolism and Disposition

Volumn 30, Issue 12, 2002, Pages 1311-1319

  Yuan, Rae ^a,b   Madani, Soraya ^a   Wei, Xiao Xiong ^a   Reynolds, Kellie ^a   Huang, Shiew Mei ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHOXY 4 TRIFLUOROMETHYLCOUMARIN O DEALKYLASE; BUFURALOL; CAFFEINE; CHLORZOXAZONE; COUMARIN 7 HYDROXYLASE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; DEXTROMETHORPHAN; MEPHENYTOIN; MEPHENYTOIN 4 HYDROXYLASE; MIDAZOLAM; PHENACETIN O DEETHYLASE; TESTOSTERONE; TOLBUTAMIDE 4 HYDROXYLASE; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; DRUG HYDROXYLATION; DRUG INDUSTRY; LIVER MICROSOME; MOLECULAR PROBE; PRIORITY JOURNAL; PROTEIN ANALYSIS; VALIDATION PROCESS; ANIMAL; DRUG INTERACTION; DRUG SCREENING; ENZYME SPECIFICITY; GENETIC PROCEDURES; HUMAN; METABOLISM; METHODOLOGY; PHYSIOLOGY;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG INTERACTIONS; HUMANS; MOLECULAR PROBE TECHNIQUES; SUBSTRATE SPECIFICITY;

EID: 0036893593     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.12.1311     Document Type: Article

References (83)

1. Boobis AR, Kahn GC, Whyte C, Brodie MJ, and Davies DS (1981) Biphasic O-deethylation of phenacetin and 7-ethoxycoumarin by human and rat liver microsomal fractions. Biochem Pharmacol 30:2451-2456.
2. Bourrie M, Meunier V, Berger Y, and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
3. Busby WF Jr, Ackermann JM, and Crespi CL (1999) Effect of methanol, ethanol, dimethyl sulfoxide and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 27:246-249.
4. Butler MA, Iwasaki M, Guengerich FP, and Kadlubar FF (1989) Human cytochrome P-450PA (P450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86:7696-7700.
5. Chauret N, Gauthier A, and Nicoll-Griffith DA (1998) Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1-4.
6. Chiba K, Kobayashi K, Tani M, Manabe K, and Ishizaki T (1993) The kinetic characterization of S-mephenytoin 4-hydroxylase (P-450IICMP) activity in human liver samples obtained as surgical waste from Japanese patients. Drug Metab Dispos 21:747-749.
7. Stereo- and regioselectivity of hepatic oxidation in man: Effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation. Eur J Clin Pharmacol 31:313-318.
8. Dayer P, Balant L, Kupfer A, Courvoisier F, and Fabre J (1983) Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of β-adrenoceptor blocking agents. Eur J Clin Pharmacol 24:797-799.
9. Draper AJ, Madan A, and Parkinson A (1997) Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 341:47-61.
10. Edwards RJ, Adams DA, Watts PS, Davies DS, and Boobis AR (1998) Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol 56:377-387.
11. Ekins S, Vandenbranden M, Ring BJ, and Wrighton SA (1997) Examination of purported probes of human CYP2B6. Phannacogenetics 7:165-179.
12. Flockhart DA (1995) Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Clin Pharmacokinet 29 (Suppl 1):45-52.
13. Francis RJ, East PB, and Larman J (1982) Kinetics and metabolism of (+)-, (-)- and (-)(±)-bufuralol. Eur J Clin Pharmacol 23:529-533.
14. Gelboin HV, Krausz KW, Shou M, Gonzalez FJ, and Yang TJ (1997) A monoclonal antibody inhibitory to human P450 2D6: A paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism. Pharmacogenetics 7:469-477.
15. Gelboin HV, Krausz KW, Goldfarb I, Buters JT, Yang SK, Gonzalez FJ, Korzekwa KR, and Shou M (1995) Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Biochem Pharmacol 50:1841-1850.
16. Ghosal A, Satoh H, Thomas PE, Bush E, and Moore D (1996) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human and cDNA-expressed human cytochrome. P450 Drug Metab Dispos 24:940-947.
17. Gibbs MA, Thummel KE, Shen DD, and Kunze KL (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: Comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
18. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, and Hall SD (1998) The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64:133-143.
19. Gorski JC, Jones DR, Wrighton SA, and Hall SD (1997) Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica 27:243-256.
20. Grant DM, Campbell ME, Tang BK, and Kalow W (1987) Biotransformation of caffeine by microsomes from human liver: Kinetics and inhibition studies. Biochem Pharmacol 36:1251-1987.
21. Gut J, Catin T, Dayer P, Kronbach T, Zanger U, and Meyer UA (1986) Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. J Biol Chem 261:11734-11743.
22. Hall SD, Guengerich FP, Branch RA, and Wilkinson GR (1987) Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J Pharmacol Exp Ther 240:216-222.
23. Hall SD, Hamman MA, Rettie AE, Wienkers LC, Trager WF, Vandenbranden M, and Wrighton SA (1994) Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. Drug Metab Dispos 22:975-978.
24. Hemeryck A, De Vriendt C, and Belpaire FM (1999) Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. Eur J Clin Pharmacol 54:947-951.
25. Heyn H, White RB, and Stevens JC (1996) Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 24:948-954.
26. Hickman D, Wang JP, Wang Y, and Unadkat JD (1998) Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 26:207-215.
27. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, and Shimada T (1997) Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7:103-113.
28. Jacqz-Aigrain E, Funck-Brentano C, and Cresteil T (1993) CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:197-204.
29. Jurima M, Inaba T, and Kalow W (1985) Mephenytoin metabolism in vitro by human liver. Drug Metab Dispos 13:151-155.
30. Kenworthy KE, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: Correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727.
31. Ko JW, Desta Z, and Flockhart DA (1998) Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. Drug Metab Dispos 26:775-778.
32. Kobayashi K, Nakajima M, Chiba K, Yamamoto T, Tani M, Ishizake, Kuroiwa Y (1998) Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalyzsed by human CYPIA2. Br J Clin Pharmacol 45:361-368.
33. Kronbach T (1991) Bufuralol, dextromethorphan and debrisoquine as prototype substrates for human P450IID6. Methods Enzymol 206:509-517.
34. Kronbach T, Mathys D, Gut J, Catin T, and Meyer UA (1987) High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 162:24-32.
35. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96.
36. Kunze KL, Eddy AC, Gibaldi M, and Trager WF (1991) Metabolic enantiomeric interactions: The inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin. Chirality 3:24-29.
37. Kunze KL, Wienkers LC, Thummel KE, and Trager WF (1996) Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies. Drug Metab Dispos 24:414-421.
38. Lang D and Bocker R (1995) Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. J Chromatogr B Biomed Appl 672:305-309.
39. Lasker JM, Wester MR, Aramsombatdee E, and Raucy JL (1998) Characterization of CYP2C19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide, S-mephenytoin and omeprazole hydroxylations. Arch Biochem Biophys 353:16-28.
40. Li Y, Li NY, and Sellers EM (1997) Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes. Eur J Drug Metab Pharmacokinet 22:295-304.
41. Mankowski DC (1999) The role of CYP2C19 in the metabolism of (+/-) bofuralol, the prototypic substrate of CYP2D6. Drug Metab Dispos 27:1024-1028.
42. Marroum PJ, Uppoorr RS, Parmelee T, Ajayi F, Burnett A, Yuan R, Svadjian R, Lesko LJ, and Balian JD (2000) In vivo drug-drug interaction studies: A survey of all new molecular entities approved from 1987 to 1997. Clin Pharmacol Ther 68:280-285.
43. Shou M (1999) Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. J Pharmacol Exp Ther 291:749-759.
44. Miners and Birkett (1996), Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9, Methods Enzymol 272:139-145.
45. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, and Birkett DJ (1988) Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic, oxidations Biochem Pharmacol 37:1137-1144.
46. Newton DJ, Wang RW, and Lu AY (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
47. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, and Gonzalez FJ (1996) Chlorzoxazone is metabolized by human CYPIA2 as well as by human CYP2EI. Pharmacogenetics 5:143-150.
48. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, and Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIEI. Chem Res Toxicol 3:566-573.
49. Pollock BG, Perel JM, Krishna M, Altieri LP, Yeager AL, Reynolds CF 3rd (1991) Smephenytoin 4-hydroxylation in older Americans. Eur J Clin Pharmacol 40:609-611.
50. Relling MV, Aoyama T, Gonzalez FJ, and Meyer UA (1990) Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 252:442-447.
51. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, and Trager WF (1992), Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59.
52. Sai Y, Yang TJ, Krausz KW, Gonzalez FJ, and Gelboin HV (1999) An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver. Pharmacogenetics 9:229-237.
53. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R, and Davies DS (1988) A form of cytochrome P450 in man, orthologous to form d in the rat, catalyzes the O-deethylation of phenacetin and is iducible by cigarette smoking. Br J Clin Pharmacol 26:363-372.
54. Sesardic D, Edwards RJ, Davies DS, Thomas PE, Levin W, and Boobis AR (1990) High affinity phenacetin O-deethylase is catalysed specifically by cytochrome P450d (P450IA2) in the liver of the rat. Biochem Pharmacol 39:489-498.
55. Shimada T, Misono KS, and Guengerich FP (1986) Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. J Biol Chem 261:909-921.
56. Shimada T, Yamazaki H, and Guengerich FP (1996) Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 26:395-403.
57. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
58. Shou M, Lu T, Krausz KW, Sai Y, Yang T, Korzekwa KR, Gonzalez FJ, and Gelboin HV (2000) Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism. Eur J Pharmacol 394:199-209.
59. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, and Crespi CL (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: Analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440-1448.
60. Stresser DM and Kupfer D (1999) Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab Dispos 27:517-525.
61. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, and Murakami T (1998) Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 358:289-294.
62. Tang C, Shou M, and Rodrigues AD (2000) Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity. Drug Metab Dispos 28:567-572.
63. Tassaneeyakul W, Birkett DJ, McManus ME, Tassaneeyakul W, Veronese ME, Andersson T, Tukey RH, and Miners JO (1994) Caffeine metabolism by human hepatic cytochromes P450: Contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 47:1767-1776.
64. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
65. Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Tukey RH, Quattrochi LC, Gonzalez FJ, and Miners JO (1992) Caffeine as a probe for human cytochromes P450: Validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 2:173-183.
66. Toon S, Low LK, Gibaldi M, Trager WF, O'Reilly RA, Motley CH, and Goulart DA (1986) The warfarin-sulfinpyrazone interaction: Stereochemical considerations. Clin Pharmacol Ther 39:15-24.
67. Tucker G, Houston JB, and Huang S-M (2001) Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential: Toward a consensus. Clin Pharmacol Ther 70:103-114; Br J Clin Pharmacol 52:107-117; Pharm Res (NY) 18:1071-1080.
68. Tucker G, Houston JB, and Huang S-M (2001) Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential: Toward a consensus. Clin Pharmacol Ther 70:103-114; Br J Clin Pharmacol 52:107-117; Pharm Res (NY) 18:1071-1080.
69. Tucker G, Houston JB, and Huang S-M (2001) Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential: Toward a consensus. Clin Pharmacol Ther 70:103-114; Br J Clin Pharmacol 52:107-117; Pharm Res (NY) 18:1071-1080.
70. Ueng YF, Kuwabara T, Chun YJ, and Guengerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-381.
71. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (1998) Human cytochromes P450 mediating phenacetin O-deethylation in vitro: Validation of the high affinity component as an index of CYPIA2 activity. J Pharm Sci 87:1502-1507.
72. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS, and Shader RI (1996) Phenacetin O-deethylation by human liver microsomes in vitro: Inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology 128:398-407.
73. Wang RW, Newton DJ, Liu N, Atkins WM, and Lu AY (2000) Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360-366.
74. Waxman DJ, Lapenson DP, Aoyama T, Gelboin HV, Gonzalez FJ, and Korzekwa K (1991) Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 290:160-166.
75. Wester MR, Lasker JM, Johnson EF, and Raucy JL (2000) CYP2C19 participates in tolbutamidc hydroxylation by human liver microsomes. Drug Metab Dispos 28:354-359.
76. Wrighton SA and Ring BJ (1994) Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, crythromycin, cimetidine and nizatidine. Pharm Res 11:921-924.
77. Wrighton SA, Ring BJ, Watkins PB, and VandenBranden M (1989) Identification of a polymorphically expressed member of the human cytochrome P-450111 family. Mol Pharmacol 36:97-105.
78. Wrighton SA, Stevens JC, Becker GW, and VandenBranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 306:240-245.
79. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, and Shimada T (1997) Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 283:434-442.
80. Yamazaki H and Shimada T (1997) Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9 and 3A4 in human liver microsomes. Arch Biochem Biophys 346:161-169.
81. Yang TJ, Krausz KW, Sai Y, Gonzalez FJ, and Gelboin HV (1999) Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin and imipramine metabolism. Drug Metab Dispos 27:102-109.
82. Yuan R, Parmelee T, Balian JD, Uppoor RS, Ajayi F, Burnett A, Lesko LJ, and Marroum P (1999) In vitro metabolic interaction studies: Experience of the Food and Drug Administration. Clin Pharmacol Ther 66:9-15.
83. Yumoto R, Murakami T, Nakamoto Y, Hasegawa R, Nagai J, and Takano M (1999) Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco 2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther 289:149-155.